Project: A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours
| Acronym | MODIFY-NK (Reference Number: 11764) |
| Duration | 01/04/2018 |
| Project Topic | The consortium will deliver a novel cell-based therapy to treat solid tumours with chimeric antigen receptors (CAR) expressing allogeneic (i.e. from a genetically non-identical donor) natural killer (NK) cells. These CARs strongly improve solid tumour targeting and killing potential. The efficacy of this clinical grade CAR-NK cell product will be validated in a preclinical solid tumour model and the therapy will be ready for clinical studies within 24 months after completion of this project. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 8 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | IPD Therapeutics BV (traded as Glycostem) | Coordinator | Netherlands |
| 2 | ImmuSmol SAS (traded as Explicyte Immuno-Oncology) | Partner | France |
| 3 | OZ Biosciences SAS | Partner | France |
| 4 | YUMAB GmbH | Partner | Germany |